An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
- Study type
- Other
- Source
- Nat Rev Clin Oncol · 2026
In plain words
This article is a piece in the journal Nature Reviews Clinical Oncology and, judging by its title, it is about how the indication (label) is worded and how patients can access the drug daraxonrasib, which the title describes as the first approved pan-RAS inhibitor. The available record has no abstract, so the details of the authors' arguments are not known. To find out which patients this drug is suitable for, talk to your treating doctor.
Clinical significance and place in guidelines
The PubMed record has no abstract, so no comment can be made on this paper's impact on clinical practice, the details of the approval or its status in guidelines. According to the title, the paper addresses the labelling of and access to daraxonrasib as the first approval of a pan-RAS inhibitor. The approval status and exact indication of the drug should be checked in the full text of the paper and in official sources from regulatory agencies.
Limitations
This card was prepared only from the title and bibliographic information of the PubMed record, and neither the abstract nor the full text was available. The exact type of article (review or perspective) is not stated in the record, nor are the related cancer(s). The journal issue and page numbers have not yet been recorded either.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.